News
Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...
Barchart on MSN5h
2 Outstanding ‘Strong Buy’ Stocks to Grab in August
For savvy investors looking for long-term businesses that not only dominate their industries today but also have the ...
CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...
Zacks Investment Research on MSN1d
Lilly Stock Down 5% This Month: Should You Buy the Dip?
Eli Lilly and Company’s LLY stock has declined 5.1% so far this month, despite announcing strong second-quarter results on ...
Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback